StockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a research report sent to investors on Monday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reaffirmed a neutral rating on shares of TRACON Pharmaceuticals in a research report on Monday, July 1st.
Get Our Latest Analysis on TCON
TRACON Pharmaceuticals Price Performance
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The firm had revenue of $0.06 million during the quarter.
TRACON Pharmaceuticals Announces Dividend
The firm also recently announced a dividend, which was paid on Monday, July 8th. Investors of record on Friday, June 28th were paid a dividend of $0.045 per share. This represents a yield of 40.3%. The ex-dividend date of this dividend was Thursday, June 27th.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
Featured Articles
- Five stocks we like better than TRACON Pharmaceuticals
- Why Invest in High-Yield Dividend Stocks?
- Emerging Markets: What They Are and Why They Matter
- Earnings Per Share Calculator: How to Calculate EPS
- Recession or Not, These 3 Stocks Are Winners
- What Are Dividend Champions? How to Invest in the Champions
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.